JP6416508B2 - Nk/t細胞リンパ腫の検査方法 - Google Patents
Nk/t細胞リンパ腫の検査方法 Download PDFInfo
- Publication number
- JP6416508B2 JP6416508B2 JP2014116444A JP2014116444A JP6416508B2 JP 6416508 B2 JP6416508 B2 JP 6416508B2 JP 2014116444 A JP2014116444 A JP 2014116444A JP 2014116444 A JP2014116444 A JP 2014116444A JP 6416508 B2 JP6416508 B2 JP 6416508B2
- Authority
- JP
- Japan
- Prior art keywords
- jak1
- mutation
- cell lymphoma
- gene
- jak3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
1.ルキソリチニブ
(in vitroヒト酵素活性阻害におけるIC50 JAK1:3.3nM、JAK2:2.8nM、JAK3:428nM、Tyk2:19nM)
骨髄線維症(EMA承認時)における用法、用量。 1回5、10、15、20、25mg、1日2回から開始。経口投与。効果が不十分な場合は、5mgずつ増量する。
2.トファシチニブ
(in vitroヒト酵素活性阻害におけるIC50 JAK1:3.2nM、JAK2:4.1nM、JAK3:1.6nM、Tyk2:34nM)
関節リウマチ(本邦承認時)における用法、用量。 1回5mg、1日2回(又は1回)経口投与。ただし、Phase2では、3、5、10、15mg BIDで、効果があることが報告されている。
1.トファシチニブ
(in vitroヒト酵素活性阻害におけるIC50 JAK1:3.2nM、JAK2:4.1nM、JAK3:1.6nM、Tyk2:34nM)
関節リウマチ(本邦承認時)における用法、用量。 1回5mg、1日2回(又は1回)経口投与。ただし、Phase2では、3、5、10、15mg BIDで、効果があることが報告されている。
Claims (3)
- NK/T細胞リンパ腫を検査する方法であって、
JAK1遺伝子のDNA配列を解析し、
前記DNA配列の解析結果から得られるアミノ酸配列の652番目のアミノ酸が、野生型であるチロシンから、アスパラギン、又はヒスチジンへ変異していることを指標として、
NK/T細胞リンパ腫を検査することを特徴とする検査方法。 - 請求項1記載のNK/T細胞リンパ腫を検査する方法であって、
さらに、JAKファミリー遺伝子のDNA配列を解析することを特徴とする検査方法。 - JAK阻害剤を探索する方法であって、
JAK1遺伝子の変異によって、JAK1タンパク質の652番目のアミノ酸が、野生型のチロシンからアスパラギン、ヒスチジンへ変異している細胞を用いて化合物をスクリーニングすることを特徴とするJAK阻害剤の探索方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014116444A JP6416508B2 (ja) | 2014-06-05 | 2014-06-05 | Nk/t細胞リンパ腫の検査方法 |
PCT/JP2015/066156 WO2015186774A1 (ja) | 2014-06-05 | 2015-06-04 | Nk/t細胞リンパ腫の検査方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014116444A JP6416508B2 (ja) | 2014-06-05 | 2014-06-05 | Nk/t細胞リンパ腫の検査方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015228825A JP2015228825A (ja) | 2015-12-21 |
JP6416508B2 true JP6416508B2 (ja) | 2018-10-31 |
Family
ID=54766842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014116444A Active JP6416508B2 (ja) | 2014-06-05 | 2014-06-05 | Nk/t細胞リンパ腫の検査方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6416508B2 (ja) |
WO (1) | WO2015186774A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111088363B (zh) * | 2020-02-22 | 2022-08-16 | 黄志清 | 基于双链dna肽连接酶的jak1基因特定突变检测试剂盒及方法 |
CN111004843B (zh) * | 2020-02-22 | 2022-08-16 | 黄志清 | 基于单链dna肽连接酶的jak1基因特定突变检测试剂盒及方法 |
CN110964834B (zh) * | 2020-02-22 | 2022-08-16 | 黄志清 | 一种jak1基因特定突变检测试剂盒及其检测方法 |
CN115074439B (zh) * | 2022-06-13 | 2023-02-28 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一组nk/t细胞淋巴瘤预后相关基因、基因组预后模型及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150292022A1 (en) * | 2011-11-25 | 2015-10-15 | Singapore Health Services Pte Ltd. | Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy |
-
2014
- 2014-06-05 JP JP2014116444A patent/JP6416508B2/ja active Active
-
2015
- 2015-06-04 WO PCT/JP2015/066156 patent/WO2015186774A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2015186774A1 (ja) | 2015-12-10 |
JP2015228825A (ja) | 2015-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Spagnolo et al. | Idiopathic pulmonary fibrosis: Disease mechanisms and drug development | |
Recondo et al. | Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer | |
Ito et al. | A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model | |
Klein et al. | BRAF inhibitor activity in V600R metastatic melanoma | |
Gardet et al. | LRRK2 is involved in the IFN-γ response and host response to pathogens | |
KR102373074B1 (ko) | 인간 ezh2의 억제제 및 이의 사용 방법 | |
KR20180021745A (ko) | 암을 진단하고 치료하는 방법 | |
Laufer-Geva et al. | The clinical impact of comprehensive genomic testing of circulating cell-free DNA in advanced lung cancer | |
Zhang et al. | Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion‐positive non–small cell lung cancer | |
JP6416508B2 (ja) | Nk/t細胞リンパ腫の検査方法 | |
JP2014516549A (ja) | ヘッジホッグ阻害剤療法のためのバイオマーカー | |
TW201409030A (zh) | 癌症之治療 | |
CN106716131B (zh) | Mdm2拮抗剂的癌症疗法的患者个性化方法 | |
US11549147B2 (en) | Treatment of atopic dermatitis with tradipitant | |
KR20140132712A (ko) | RNF43 돌연변이 상태를 사용한 Wnt 신호전달 억제제의 투여를 위한 암 환자 선택 | |
Shi et al. | BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer | |
Ono et al. | Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity | |
RU2663701C2 (ru) | Маркеры, ассоциированные с ингибиторами wnt | |
Jamme et al. | Relevance of detection of mechanisms of resistance to ALK inhibitors in ALK-rearranged NSCLC in routine practice | |
CN114901289A (zh) | 用于治疗alk阴性癌症和浆细胞介导的疾病的alk抑制剂 | |
Lietman et al. | Targeting GNAQ/11 through PKC inhibition in uveal melanoma | |
Cano et al. | Application of kinase inhibitors for anti-aging intervention | |
EP2782562B1 (en) | Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy | |
Chi et al. | Phase Ib trial of the combination of imatinib and binimetinib in patients with advanced gastrointestinal stromal tumors | |
Friedman et al. | Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180509 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180918 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181004 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6416508 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |